MELAS is characterized by systemic clinical manifestations including stroke, recurrent headaches, epilepsy, hearing impairment, myopathy, dementia, ataxia and diabetes.[3] The m.3243A > G mutation in the MT-TL1 gene[4,5] accounts for almost 80% of the abnormalities in MELAS patients. Here, MT-TL1 is linked to MELAS.